Peak Values of G-CSF Serum Levels and Leukocyte Counts After Repeated Injections of SDZ MRL 953 (34.2/39.6 μg/kg, n = 6) or Vehicle Control (n = 5) in Cancer Patients
| Day | 1 | 3 | 8 | 10 | 29 | 31 | 33 |
| Treatment | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| G-CSF (pg/mL) | |||||||
| SDZ MRL 953 | 227.4 ± 142.5 | 147.8 ± 98.8 | 75.3 ± 21.5 | 133.8 ± 53.5 | 194.6 ± 87.8 | 201.4 ± 87.6 | 80.5 ± 27.0 |
| Vehicle control | 23.5 ± 3.3 | 25.9 ± 5.6 | 29.8 ± 10.7 | 26.2 ± 2.6 | 20.6 ± 3.5 | 21.9 ± 5.1 | 24.6 ± 6.5 |
| Leukocytes (×109/L) | |||||||
| SDZ MRL 953 | 10.1 ± 1.0 | 9.8 ± 0.6 | 8.7 ± 1.0 | 9.3 ± 0.8 | 9.7 ± 0.9 | 8.7 ± 1.1 | 7.3 ± 0.5 |
| Vehicle control | 6.0 ± 0.5 | 5.5 ± 0.7 | 5.6 ± 0.8 | 5.7 ± 1.0 | 6.4 ± 0.7 | 6.2 ± 0.7 | 5.5 ± 0.7 |
| Day | 1 | 3 | 8 | 10 | 29 | 31 | 33 |
| Treatment | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| G-CSF (pg/mL) | |||||||
| SDZ MRL 953 | 227.4 ± 142.5 | 147.8 ± 98.8 | 75.3 ± 21.5 | 133.8 ± 53.5 | 194.6 ± 87.8 | 201.4 ± 87.6 | 80.5 ± 27.0 |
| Vehicle control | 23.5 ± 3.3 | 25.9 ± 5.6 | 29.8 ± 10.7 | 26.2 ± 2.6 | 20.6 ± 3.5 | 21.9 ± 5.1 | 24.6 ± 6.5 |
| Leukocytes (×109/L) | |||||||
| SDZ MRL 953 | 10.1 ± 1.0 | 9.8 ± 0.6 | 8.7 ± 1.0 | 9.3 ± 0.8 | 9.7 ± 0.9 | 8.7 ± 1.1 | 7.3 ± 0.5 |
| Vehicle control | 6.0 ± 0.5 | 5.5 ± 0.7 | 5.6 ± 0.8 | 5.7 ± 1.0 | 6.4 ± 0.7 | 6.2 ± 0.7 | 5.5 ± 0.7 |
Values are the mean ± SEM.